FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087996866> ?p ?o ?g. }

• W3087996866 endingPage "S1040" @default.
• W3087996866 startingPage "S1040" @default.
• W3087996866 abstract "Existing maintenance treatment strategies for patients with extensive-stage small cell lung cancer (ES-SCLC) experiencing no progression after the standard first-line chemotherapy are limited. Previous analysis in ALTER1202 showed anlotinib, a novel oral multitarget tyrosine kinase inhibitor, significantly prolonged progression-free survival (PFS) and overall survival (OS) in relapsed SCLC who failed ≥ 2 lines of chemotherapy. The aim of this study was to assess the efficacy and safety of anlotinib combined with etoposide as maintenance treatment in patients with ES-SCLC after the standard first-line EP chemotherapy. Patients with histologically confirmed ES-SCLC who have not progressed after the standard first-line EP chemotherapy received anlotinib (12 mg, QD, from day 1 to 14, every 3 weeks) combined with etoposide (50 mg, QD, day 1 to 14 of a 21-day cycle, up to 6 cycles) until disease progression or unacceptable toxicity. The primary endpoint was PFS. Secondary endpoints were OS and safety. The study was registered at Chinese Clinical Trial Registry (ChiCTR1800019421). Between April 2019 and January 2020, we screened 15 patients and enrolled 12 patients in this trial. At data cut-off (April 30, 2020), 6 (50%) patients had discontinued the study, and 6 (50%) patients remained on treatment. The median follow-up time was 4.30 month (95% Cl, 3.25-5.36). Among the 12 patients, 4 patients reached partial response (PR) and 7 had stable disease (SD). The median PFS (mPFS) was not reached and the six-month PFS rate was 68.8% (95%CI, 44.0%-100%). The objective response rate (ORR) and the disease control rate (DCR) were 33.3% and 91.6%, respectively. The most common grade 1-2 adverse events (AEs) included anorexia (8 of 12, 66.7%), hypertension (7 of 12, 58.3%), fatigue (4 of 12, 33.3%) and vomiting (4 of 12, 33.3%). No grade 3 or higher AEs were observed. The combination of anlotinib and etoposide appeared to have significant efficacy and favorable safety profile as maintenance treatment in patients with ES-SCLC having not progressed after the standard first-line EP chemotherapy.The further exploration is ongoing." @default.
• W3087996866 created "2020-10-01" @default.
• W3087996866 creator A5057872518 @default.
• W3087996866 creator A5061976160 @default.
• W3087996866 creator A5070813860 @default.
• W3087996866 creator A5078438651 @default.
• W3087996866 date "2020-09-01" @default.
• W3087996866 modified "2023-09-25" @default.
• W3087996866 title "1795P Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): A single-arm, prospective phase II study" @default.
• W3087996866 doi "https://doi.org/10.1016/j.annonc.2020.08.1556" @default.
• W3087996866 hasPublicationYear "2020" @default.
• W3087996866 type Work @default.
• W3087996866 sameAs 3087996866 @default.
• W3087996866 citedByCount "0" @default.
• W3087996866 crossrefType "journal-article" @default.
• W3087996866 hasAuthorship W3087996866A5057872518 @default.
• W3087996866 hasAuthorship W3087996866A5061976160 @default.
• W3087996866 hasAuthorship W3087996866A5070813860 @default.
• W3087996866 hasAuthorship W3087996866A5078438651 @default.
• W3087996866 hasBestOaLocation W30879968661 @default.
• W3087996866 hasConcept C126322002 @default.
• W3087996866 hasConcept C141071460 @default.
• W3087996866 hasConcept C143998085 @default.
• W3087996866 hasConcept C203092338 @default.
• W3087996866 hasConcept C2776256026 @default.
• W3087996866 hasConcept C2776694085 @default.
• W3087996866 hasConcept C2778119113 @default.
• W3087996866 hasConcept C2778283404 @default.
• W3087996866 hasConcept C2778336483 @default.
• W3087996866 hasConcept C2778822529 @default.
• W3087996866 hasConcept C2780739268 @default.
• W3087996866 hasConcept C31760486 @default.
• W3087996866 hasConcept C535046627 @default.
• W3087996866 hasConcept C71924100 @default.
• W3087996866 hasConcept C90924648 @default.
• W3087996866 hasConceptScore W3087996866C126322002 @default.
• W3087996866 hasConceptScore W3087996866C141071460 @default.
• W3087996866 hasConceptScore W3087996866C143998085 @default.
• W3087996866 hasConceptScore W3087996866C203092338 @default.
• W3087996866 hasConceptScore W3087996866C2776256026 @default.
• W3087996866 hasConceptScore W3087996866C2776694085 @default.
• W3087996866 hasConceptScore W3087996866C2778119113 @default.
• W3087996866 hasConceptScore W3087996866C2778283404 @default.
• W3087996866 hasConceptScore W3087996866C2778336483 @default.
• W3087996866 hasConceptScore W3087996866C2778822529 @default.
• W3087996866 hasConceptScore W3087996866C2780739268 @default.
• W3087996866 hasConceptScore W3087996866C31760486 @default.
• W3087996866 hasConceptScore W3087996866C535046627 @default.
• W3087996866 hasConceptScore W3087996866C71924100 @default.
• W3087996866 hasConceptScore W3087996866C90924648 @default.
• W3087996866 hasLocation W30879968661 @default.
• W3087996866 hasOpenAccess W3087996866 @default.
• W3087996866 hasPrimaryLocation W30879968661 @default.
• W3087996866 hasRelatedWork W2054340543 @default.
• W3087996866 hasRelatedWork W2120667391 @default.
• W3087996866 hasRelatedWork W2620160838 @default.
• W3087996866 hasRelatedWork W2770020152 @default.
• W3087996866 hasRelatedWork W2898395149 @default.
• W3087996866 hasRelatedWork W3000437623 @default.
• W3087996866 hasRelatedWork W3135827372 @default.
• W3087996866 hasRelatedWork W4253848392 @default.
• W3087996866 hasRelatedWork W4286299135 @default.
• W3087996866 hasRelatedWork W4304690509 @default.
• W3087996866 hasVolume "31" @default.
• W3087996866 isParatext "false" @default.
• W3087996866 isRetracted "false" @default.
• W3087996866 magId "3087996866" @default.
• W3087996866 workType "article" @default.